The impact of extramedullary disease at presentation on the outcome of myeloma
- 1 January 2009
- journal article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 50 (2), 230-235
- https://doi.org/10.1080/10428190802657751
Abstract
This study was conducted to compare the presenting features and outcome of newly-diagnosed myeloma with and without extramedullary (EM) manifestations and to determine the optimum treatment. Seventy-five (16.3%) patients with EM involvement at diagnosis were compared with 384 cases without EM disease. EM patients had a more favourable International Staging System and a different distribution of myeloma isotypes. When adjusted according to the independent risk factors, patients in the EM group treated with chemotherapy alone had significantly shorter overall survival (OS) compared to those without EM disease receiving similar treatment. High-dose treatment (HDT) was associated with significantly improved OS in both groups; however, it had more impact on OS among EM group, overcoming the negative prognostic impact of presenting EM disease. Patients in the EM group treated with HDT have a similar outcome to those without EM manifestations treated with HDT. HDT should form an integral component of first-line treatment for patients with EM disease whenever possible.Keywords
This publication has 13 references indexed in Scilit:
- Bortezomib in combination with thalidomide and dexamethasone—a successful treatment regimen in refractory extramedullary multiple myelomaAnnals of Hematology, 2007
- Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moonLeukemia Research, 2007
- Bortezomib: an effective agent in extramedullary disease in multiple myelomaEuropean Journal of Haematology, 2006
- The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysisLeukemia & Lymphoma, 2006
- Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single centerEuropean Journal of Haematology, 2004
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Thalidomide in multiple myeloma: lack of response of soft‐tissue plasmacytomasBritish Journal of Haematology, 2001
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Presenting Features and Prognosis in 72 Patients With Multiple Myeloma Who Were Younger Than 40 YearsBritish Journal of Haematology, 1996